z-logo
Premium
Norepinephrine infusion improves haemodynamics in the preterm infants during septic shock
Author(s) -
Rizk MY,
Lapointe A,
Lefebvre F,
Barrington KJ
Publication year - 2018
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/apa.14112
Subject(s) - medicine , norepinephrine , septic shock , anesthesia , hemodynamics , blood pressure , gestational age , inotrope , shock (circulatory) , mean arterial pressure , urine , urine output , sepsis , heart rate , cardiology , pregnancy , creatinine , biology , genetics , dopamine
Aim This study evaluated the clinical and haemodynamic effects of norepinephrine infusion in preterm infants. Methods The effects of norepinephrine therapy for refractory hypotension were evaluated in preterm infants between April 2009 and April 2011 at the neonatal intensive care unit of Sainte‐Justine Hospital, Montreal, Quebec. Changes in haemodynamics and clinical parameters were analysed eight hours before and eight hours after the start of norepinephrine infusion, and eight hours after its cessation. Results During the study , 30 preterm infants at a mean gestational age of 26.5 ± 2.6 weeks (median: 25.7, 23.4–34) and birthweight of 903 ± 437 g (median 827, 450–2550) received norepinephrine infusion for neonatal septic shock. After eight hours of treatment, mean blood pressure, urine output and FiO 2 significantly improved. Eight hours after cessation of norepinephrine infusion, the number of patients treated with other inotropes decreased significantly, 24 patients (80%) had normal mean blood pressure and 27 patients (90%) had normal urine output. Conclusion Norepinephrine therapy could be considered to improve blood pressure and urine output during neonatal septic shock in preterm infants. Further studies are needed to prove the efficacy and safety of norepinephrine infusion in neonates.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here